Engineered MSCs enable bone marrow-targeted immunomodulation
{{output}}
Tumors are increasingly recognized as a consequence of systemic immune dysregulation, while current therapies merely focus on direct tumor killing or local immune activation, overlooking the systemic immune landscape that enables tumorigenesis and metastasis. ... ...